Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas
Published On: 09/13/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced the initiation of its Phase 2/3 POPLAR-NF2 clinical trial during the Children's Tumor Foundation NF Conference. The trial will evaluate REC-2282: a potentially first-in-disease, orally bioavailable, central nervous system (CNS) penetrant small molecule histone deacetylase (HDAC) inhibitor, for the treatment of progressive neurofibromatosis type 2 (NF2)-mutated meningiomas.
If successful, REC-2282 could be the first approved treatment for NF2-mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per year. REC-2282 has been granted Fast Track and Orphan Drug designations for NF2 meningiomas by the U.S. Food and Drug Administration, as well as Orphan Drug designation for NF2 meningiomas by the European Commission.